Want to see TLX full AI Analyst Report?
Total Valuation
Telix Pharmaceuticals Limited Unsponsored ADR has a market cap or net worth of $4.01B. The enterprise value is 4.44K.
Market Cap$4.01B
Enterprise Value4.44K
Share Statistics
Telix Pharmaceuticals Limited Unsponsored ADR has 339,892,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding339,892,360
Owned by Insiders―
Owned by Institutions0.25%
Financial Efficiency
Telix Pharmaceuticals Limited Unsponsored ADR’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is 1.83%.
Return on Equity (ROE)-0.02
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)1.83%
Return on Capital Employed (ROCE)0.02
Revenue Per Employee1.05M
Profits Per Employee-9.28K
Employee Count1,152
Asset Turnover0.68
Inventory Turnover10.17
Valuation Ratios
The current PE Ratio of Telix Pharmaceuticals Limited Unsponsored ADR is 116.2. Telix Pharmaceuticals Limited Unsponsored ADR’s PEG ratio is 2.93.
PE Ratio116.2
PS Ratio3.15
PB Ratio6.09
Price to Fair Value6.09
Price to FCF-45.79
Price to Operating Cash Flow-249.94
PEG Ratio2.93
Income Statement
In the last 12 months, Telix Pharmaceuticals Limited Unsponsored ADR had revenue of 1.21B and earned -10.69M in profits. Earnings per share was -0.03.
Revenue1.21B
Gross Profit640.23M
Operating Income26.64M
Pretax Income-7.90M
Net Income-10.69M
EBITDA79.83M
Earnings Per Share (EPS)-0.03
Cash Flow
In the last 12 months, operating cash flow was -19.19M and capital expenditures -67.52M, giving a free cash flow of -86.70M billion.
Operating Cash Flow-19.19M
Free Cash Flow-86.70M
Free Cash Flow per Share-0.26
Dividends & Yields
Telix Pharmaceuticals Limited Unsponsored ADR pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change11.47%
50-Day Moving Average11.31
200-Day Moving Average9.59
Relative Strength Index (RSI)46.74
Average Volume (3m)289.64K
Important Dates
Telix Pharmaceuticals Limited Unsponsored ADR upcoming earnings date is Feb 19, 2027, TBA (Not Confirmed).
Last Earnings DateAug 19, 2026
Next Earnings DateFeb 19, 2027
Ex-Dividend Date―
Financial Position
Telix Pharmaceuticals Limited Unsponsored ADR as a current ratio of 1.43, with Debt / Equity ratio of 118.90%
Current Ratio1.43
Quick Ratio1.27
Debt to Market Cap0.16
Net Debt to EBITDA6.10
Interest Coverage Ratio0.48
Taxes
In the past 12 months, Telix Pharmaceuticals Limited Unsponsored ADR has paid 2.79M in taxes.
Income Tax2.79M
Effective Tax Rate-0.35
Enterprise Valuation
Telix Pharmaceuticals Limited Unsponsored ADR EV to EBITDA ratio is 53.59, with an EV/FCF ratio of -51.68.
EV to Sales3.55
EV to EBITDA53.59
EV to Free Cash Flow-51.68
EV to Operating Cash Flow-164.98
Balance Sheet
Telix Pharmaceuticals Limited Unsponsored ADR has $363.63M in cash and marketable securities with $837.03M in debt, giving a net cash position of -$473.40M billion.
Cash & Marketable Securities$363.63M
Total Debt$837.03M
Net Cash-$473.40M
Net Cash Per Share-$1.39
Tangible Book Value Per Share-$0.79
Margins
Gross margin is 52.16%, with operating margin of 2.21%, and net profit margin of -0.89%.
Gross Margin52.16%
Operating Margin2.21%
Pretax Margin-0.66%
Net Profit Margin-0.89%
EBITDA Margin6.62%
EBIT Margin3.91%
Analyst Forecast
The average price target for Telix Pharmaceuticals Limited Unsponsored ADR is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast33.78%
EPS Growth Forecast198.49%